Article Text

Download PDFPDF

4CPS-038 Stability to high temperatures of the antimicrobials used in outpatient parenteral antimicrobial therapy programmes
  1. M Mejias Trueba1,
  2. L Herrera Hidalgo1,
  3. JL Pérez Blanco1,
  4. MV Gil Navarro1,
  5. LE López Cortés2,
  6. JM Carmona Caballero3,
  7. R Luque Márquez4
  1. 1Hospital Universitario Virgen Del Rocío, Hospital Pharmacy, Sevilla, Spain
  2. 2Instituto De Biomedicina De Sevilla Ibis, Clinical Unit of Infectious Diseases-Microbiology and Preventive Medicine, Sevilla, Spain
  3. 3Hospital Universitario Virgen Del Rocío, Pharmacy, Sevilla, Spain
  4. 4Hospital Universitario Virgen Del Rocío, Clinical Unit of Infectious Diseases-Microbiology and Preventive Medicine, Sevilla, Spain


Background and importance Outpatient parenteral antimicrobial therapy (OPAT) programmes allow the administration of intravenous antimicrobials to non-hospitalised patients, offering numerous advantages. During administration, antimicrobial solutions could experience an increase in temperature after exposure to room temperature. However, studies on stability at high temperatures (35–37°C) are still very scarce.

Aim and objectives To collect high temperature stability data (35–37°C) for antimicrobials used in an OPAT programme.

Material and methods Antimicrobials used in the OPAT programme of two third level hospitals were compiled. Different sources of information were consulted (data sheet, Stabilis and Micromedex) to find stability studies for each antimicrobial at high temperatures (35–37°C). Data were classified in three groups: antimicrobials with stability data at concentrations used in OPAT, antimicrobials with stability data at other concentrations and antimicrobials without stability data.

Results The stability of 24 antimicrobials was studied: in 16.66% of cases, stability studies were found at the temperatures mentioned for the concentrations used; in 50% of cases there were stability data, but for concentrations other than those used in clinical practice and in the remaining 33.33%, there were no published data for the aforementioned temperatures.

  • Stability data found:

    1. At the concentrations used: acyclovir 3–5 mg/mL (2 weeks), cefazolin 12.5–25 mg/mL (12 hours), gentamicin 2.5 mg/mL (96 hours) and voriconazole 2 mg/mL (4 hours).

    2. Other than the concentrations used: aztreonam 60 or 100 mg/mL (24 hours), ampicillin 0.0125 mg/mL (24 hours), cefepime 0.5 mg/mL (4 hours) and 50 mg/mL (13 hours), ceftazidime 0.1 mg/mL (2 hours) and 120 mg/mL (8 hours), ceftriaxone 10 mg/mL (2 weeks), clindamycin 0.25 mg/mL (24 hours), daptomycin 100 mg/mL (6 hours), meropenem 5 mg/mL (4 hours), piperacillin–tazobactam 128/16 mg/mL (24 hours), penicillin G 0.13 MUI/mL (5 hours), tobramycin 20 mg/mL (3 weeks) and vancomycin 1 mg/mL (4 days).

    3. Antimicrobials without studies at high temperatures: amphotericin B, cloxacillin, ertapenem, foscarnet, fluconazole, ganciclovir, sulbactam and teicoplanin.

Conclusion and relevance

  • Stability data at high temperatures were scarce for the antimicrobials used in the OPAT programme. It would be convenient to carry out corresponding studies.

  • In warm environments, where the OPAT programme is established, antimicrobials and their concentrations should be adapted to the available information.

References and/or acknowledgements No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.